Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection

AAPS Journal

Volumn 16, Issue 1, 2014, Pages 37-47

  Zhou, Qi ^a   Gengenbach, Thomas ^b   Denman, John A ^c   Yu, Heidi H ^d   Li, Jian ^d   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CSIRO   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Combination antibiotics; Dry powder inhaler; Moisture protection; Respiratory infection; Synergistic antibacterial activity

Indexed keywords

COLISTIN; RIFAMPICIN;

ACINETOBACTER BAUMANNII; AEROSOL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; DRUG POTENTIATION; HUMIDITY; MINIMUM INHIBITORY CONCENTRATION; MOISTURE; NONHUMAN; PARTICLE SIZE; PERFORMANCE MEASUREMENT SYSTEM; POWDER; SPRAY DRYING; SURFACE PROPERTY; TIME OF FLIGHT MASS SPECTROMETRY; X RAY DIFFRACTION; X RAY PHOTOELECTRON SPECTROSCOPY;

ACINETOBACTER BAUMANNII; ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; HUMIDITY; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; PARTICLE SIZE; PHOTOELECTRON SPECTROSCOPY; POWDERS; RESPIRATORY TRACT INFECTIONS; RIFAMPIN;

EID: 84893113797     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9537-8     Document Type: Article

References (44)

1. Edwards B, Jenkins C. The Australian Lung Foundation's Case Statement: respiratory infectious disease burden in Australia. Austrlian Lung Found. 2007: p9.
2. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953-8. doi:10.1128/aac.00035-06.
3. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant in Gram-negative bacteria. Int J Antimicrob Agents. 2005;25(1):11-25. doi:10.1016/j.ijantimicag.2004.10.001.
4. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284-94. doi:10.1128/aac.01733-10.
5. Antoniu SA, Cojocaru I. Inhaled colistin for lower respiratory tract infections. Expert Opin Drug Deliv. 2012;9(3):333-42. doi:10.1517/17425247.2012. 660480.
6. Traini D, Young PM. Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv. 2009;6(9):897-905. doi:10.1517/ 17425240903110710.
7. Schuster A, Haliburn C, Döring G, Goldman MH, Group ft FS. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68(4):344-50. doi:10.1136/thoraxjnl-2012-202059.
8. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;57(2):306-11. doi:10.1093/jac/dki461.
9. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1-2):1-19. doi:10.1016/j.ijpharm. 2010.03.017.
10. Geller DE, Konstan MW, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42(4):307-13. doi:10.1002/ppal.20594.
11. Le Brun PPH, de Boer AH, Mannes GPM, de Fraiture DMI, Brimicombe RW, Touw DJ, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2 inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm. 2002;54(1):25-32. doi:10.1016/s0939-6411(02)00044-9.
12. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535-43. doi:10.1097/QCO.0b013e328332e672.
13. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50(9):2946-50. doi:10.1128/aac.00103-06.
14. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14(9):816-27.
15. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 1998;41(4):494-5. doi:10.1093/jac/41.4.494.
16. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Tsaganos T, Dontas I, Koutoukas P, et al. Colistin offers prolonged survival in experimental infection by multidrugresistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents. 2007;29(1):51-5. doi:10.1016/j.ijantimicag.2006.09.009.
17. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis. 2007;45(5):594-8. doi:10.1086/520658.
18. Chan JGY, Chan HK, Prestidge CA, Denman JA, Young PM, Traini D. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm. 2013;83(2):285-92. doi:10.1016/j.ejpb.2012. 08.007.
19. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471-84. doi:10.1128/aac.01464-06.
20. Zhou QT, Denman JA, Gengenbach T, Das S, Qu L, Zhang H, et al. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J Pharm Sci. 2011;100(8):3421-30.
21. Beamson G, Briggs D. High resolution XPS of organic polymers. 1st ed. Chichester: Wiley; 1992.
22. Zhou QT, Qu L, Gengenbach T, Denman JA, Larson I, Stewart PJ, et al. Investigation of the extent of surface coating via mechanofusion with varying additive levels and the influences on bulk powder flow properties. Int J Pharm. 2011;413(1-2):36-43.
23. Asking L, Olsson B. Calibration at different flow rates of a multistage liquid impinger. Aerosol Sci Technol. 1997;27(1):39-49. doi:10.1080/ 02786829708965456.
24. Pilcer G, Vanderbist F, Amighi K. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties. J Pharm Sci. 2009;98(4):1463-75. doi:10.1002/jps.21545.
25. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med-Depos Clearance Eff Lung. 1993;6(2):99-110. doi:10.1089/jam.1993.6.99.
26. Zhou QT, Tong Z, Tang P, Citterio M, Yang R, Chan H-K. Effect of device design on the aerosolization of a carrier-based dry powder inhaler-a case study on Aerolizer® Foradile®. AAPS J. 2013;15(2):511-22. doi:10.1208/s12248- 013-9458-6.
27. Zhou QT, Morton DAV, Yu HH, Jacob J, Wang J, Li J, et al. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation. J Pharm Sci. 2013;102(10):3736-3747.
28. Zhang J, Wu L, Chan H-K, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev. 2011;63(6):441-55. doi:10.1016/j.addr.2010.11.002.
29. Kim CS, Jaques PA. Analysis of total respiratory deposition of inhaled ultrafine particles in adult subjects at various breathing patterns. Aerosol Sci Technol. 2004;38(6):525-40. doi:10.1080/02786820490465513.
30. Zhu KW, Tan RBH, Ng WK, Shen S, Zhou Q, Heng PWS. Analysis of the influence of relative humidity on the moisture sorption of particles and the aerosolization process in a dry powder inhaler. J Aerosol Sci. 2008;39(6):510-24. doi:10.1016/j.jaerosci.2008.02.003.
31. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601. doi:10.1016/s1473- 3099(06)70580-1.
32. Song JY, Lee J, Heo JY, Noh JY, Kim WJ, Cheong HJ, et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2008;32(3):281-4. doi:10.1016/j.ijantimicag.2008.04.013.
33. Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(8):3738-45. doi:10.1128/aac.00703-13.
34. European Medicines Agency 2012. Colobreathe: European public assessment report (EPAR)-Product Information.
35. Zhou Q, Morton DAV. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. Adv Drug Deliv Rev. 2012;64(3):275-84. doi:10.1016/j.addr. 2011.07.002.
36. de Boer AH, Le Brun PPH, van der Woude HG, Hagedoorn P, Heijerman HGM, Frijlink HW. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm. 2002;54(1):17-24. doi:10.1016/s0939-6411(02)00043-7.
37. Chew NYK, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res. 2001;18(11):1570-7. doi:10.1023/a:1013082531394.
38. de Boer AH, Hagedoorn P, Woolhouse R, Wynn E. Computational fluid dynamics (CFD) assisted performance evaluation of the Twincer (TM) disposable high-dose dry powder inhaler. J Pharm Pharmacol. 2012;64(9):1316-25. doi:10.1111/j.2042-7158.2012.01511.x.
39. Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer AH. Characterisation of high dose aerosols fromdry powder inhalers. Int J Pharm. 2012;437(1-2):242-9. doi:10.1016/j.ijpharm.2012.08.020.
40. Zhou QT, Armstrong B, Larson I, Stewart PJ, Morton DAV. Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. Eur J Pharm Sci. 2010;40(5):412-21. doi:10.1016/j.ejps.2010.04.012.
41. Feeley JC, York P, Sumby BS, Dicks H. Processing effects on the surface properties of alpha-lactose monohydrate assessed by inverse gas chromatography (IGC). J Mater Sci. 2002;37(1):217-22. doi:10.1023/a:1013103521464.
42. de Boer AH, Hagedoorn P, Westerman EM, Le Brun PPH, Heijerman HGM, Frijlink HW. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. Eur J Pharm Sci. 2006;28(3):171-8. doi:10.1016/j.ejps.2005.11.013.
43. Kumon M, Kwok PCL, Adi H, Heng D, Chan HK. Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J Pharm Sci. 2010;40(1):16-24. doi:10.1016/j.ejps.2010.02.004.
44. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999-1022. doi:10.1007/s11095-007-9475-1.